-+ 0.00%
-+ 0.00%
-+ 0.00%

Vor Bio appoints former Verona Pharma CEO David Zaccardelli to board

PUBT·07/07/2026 20:01:25
Listen to the news
Vor Bio appoints former Verona Pharma CEO David Zaccardelli to board
  • Vor Bio appointed David Zaccardelli to its board, adding a biotech executive with more than 20 years of industry leadership experience.
  • Zaccardelli was CEO of Verona Pharma from 2020 until its USD 10 billion acquisition by Merck in October 2025.
  • He previously led Dova Pharmaceuticals through its sale to Swedish Orphan Biovitrum in 2019 for up to USD 915 million.
  • RA Capital Management advisor Andrew Levin stepped down from the board in connection with the appointment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607071601PRIMZONEFULLFEED9758409) on July 07, 2026, and is solely responsible for the information contained therein.